Full Length Research Paper
References
|
Abruquah HH (2012). Prevalence and antifungal susceptibility of Candida species isolated from women attending a gynaecological clinic in Kumasi, Ghana. J. Sci. Technol. 32(2):39-45. |
|
|
Adjapong G, Hale Mand, Garrill A (2014). An investigation of the distribution of Candida species in genitourinary candidiasis and pelvic inflammatory disease from three locations in Ghana. Afr. J. Microbiol. Res. 8(6):470-475. |
|
|
Anane S, Kaouech E, Zouari B, Belhadj S, Kallel K, Chaker E 2010. Les candidoses vulvovaginales: facteurs de risque et particularitéscliniques et mycologiques. J. Mycol. Med. 20:36-41. |
|
|
Arnold HM, MicekST, ShorrAF, Zilberberg MD, Labelle AJ, Kothari S, Kollef MH (2010). Hospital resource utilization and costs of inappropriate treatment of candidemia. Pharmacotherapy 30:361-368. |
|
|
Benchellal M, Guelzim K, Lemkhente Z, Jamili H, Dehainy M, RahaliMoussaoui D, El Mellouki W, Sbai Idrissi K, Lmimouni B (2011). La candidose vulvovaginale à l'hôpital militaire d'instruction Mohammed V (Maroc). J. Mycol. Med. 21:106-112. |
|
|
Bonouman-Ira V, Angora E, Djohan V, Vanga-BossonH, Sylla-Thanon K, Beourou S, Toure AO, Faye-Ketté H, Dosso M, Koné M (2011). Profil de résistance des Candida non albicans à Abidjan en 2011. Rev. Bio-Afr. 9:27-31. |
|
|
Deorukhkar SC, Saini S (2013). Vulvovaginal Candidiasis due to non albicans Candida: its species distribution and antifungal susceptibility profile. Int. J. Curr. Microbiol. Appl. Sci. 2(12):323-328. |
|
|
Diekema D, Arbefeville S, Boyken L, Kroeger J, Pfaller M (2012). The changing epidemiology of healthcare-associated candidemia over three decades. Diagn. Microbiol. Infect. Dis. 73:45-48. |
|
|
Djohan V, Angora KE, Vanga-Bosson AH, Konaté A, Kassi FK, Yavo W, Kiki-Barro PC, Menan H, Koné M (2011).Sensibilité in vitro des souches de Candida albicans d'origine vaginale aux antifongiques à Abidjan (Côte d'Ivoire). J. Mycol. Med. 22:129-133. |
|
|
Enwuru CA, Ogunledun A, Idika N, Enwuru NV, Ogbonna E, Aniedobe A, Adiega A (2008). Fluconazole resistant opportunistic oropharyngeal Candida and non-Candida yeast-like isolates from HIV infected patients attending ARV clinics in Lagos, Nigeria. Afr. Health Sci. 8:142-148. |
|
|
Feglo PK, Narkwa P (2012). Prevalence and antifungal susceptibility patterns of yeast isolates at the Komfo Anokye Teaching Hospital (KATH), Kumasi, Ghana. Br. J. Microbiol. Res. 2:10-22. |
|
|
Gandhi TN, Patel MG, Jain MR (2015). Antifungal susceptibility of candida against six antifungal drugs by disk diffusion method isolated from vulvovaginal candidiasis. Int. J. Cur. Res. Rev. 7(11):20-25. |
|
|
Kauffman CA, Fisher JF, Sobel JD, Newman CA (2011). Candida Urinary Tract Infections-Diagnosis. Clin. Infect. Dis. 52 (Suppl 6):S452-S456. |
|
|
Khan PA, Fatima N, SarvarJahan N, Khan HM, Malik A (2015). Antifungal susceptibility pattern of candida Isolates from a tertiary care Hospital of North India: A Five Year Study. Int. J. Curr. Microbiol. Appl. Sci. 1:177-181. |
|
|
Kiguli JM, Itabangi H, Atwine D, Kibuka LS, Bazira J, Byarugaba F (2015). Antifungal Susceptibility Patterns of Vulvovaginal Candida species among Women Attending Antenatal Clinic at Mbarara Regional Referral Hospital, South Western Uganda. Br. J. Microbiol. Res. 5(4):322-331. |
|
|
Konate A, Yavo W, Kassi FK, Djohan V, Angora EK, Barro-Kiki PC, Bosson-Vanga H, Soro F, Menan EIH (2014). Aetiologies and contributing factors of vulvovaginal candidiasis in Abidjan (Cote d'Ivoire). J. Mycol. Med. 24:93-99. |
|
|
Li H, Zhang C, Chen Z, Shi W, Sun S (2014). A promising approach of overcoming the intrinsic resistance of Candida krusei to fluconazole (FLC)-combining tacrolimus with FLC. FEMS Yeast Res. 14:808-811. |
|
|
Malar ASS, Viswanathan T, Malarvizhi A, Lavanya V, Moorthy K (2012). Isolation, characterisation and antifungal susceptibility Pattern of Candida albicans and non albicans Candida from Integrated counseling and testing centre (ICTC) patients. Afr. J. Microbiol. Res. 6(31):6039-6048. |
|
|
Mondal S, Mondal A, Pal N, Banerjee P, Kumar S, Bhargava D (2013). Species distribution and in vitro antifungal susceptibilitypatterns of Candida. J. Inst. Med. 35(1):45-49. |
|
|
Moyes DL, Naglik JR (2011). Mucosal immunity and Candida albicans infection. Clin. Dev. Immunol. 2011:346307. |
|
|
National Committee for Clinical Laboratory Standards (1997).Reference Method for Broth dilution. Antifungal Susceptibility Testing of Yeasts; Approved Standard. Document M27-A 17, 1/29 |
|
|
Pfaller MA, Andes D, Arendrup MC, Diekema DJ, Espinel-Ingroff A, Alexander BD, Brown SD, Chaturvedi V, Fowler CL, Ghannoum MA, Johnson EM, Knapp CC, Motyl MR, Ostrosky-Zeichner L, Walsh TJ (2011). Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of speciesspecific interpretive criteria. Diagn. Microbiol. Infect. Dis. 3:330-343. |
|
|
Prasad R, Rawal MK (2014). Efflux pump proteins in antifungal resistance. Front Pharmacol. 5:202. |
|
|
Salehei Z, Seifi Z, Zarei A, Mahmoudabadi A (2012). Sensitivity of Vaginal Isolates of Candida to Eight Antifungal Drugs Isolated From Ahvaz, Iran. Jundishapur J. Microbiol. 5(4):574-577. |
|
|
Zhang L, Wang H, Xiao M, Kudinha T, Mao L, Zhao HR, Kong F, Xu YC (2014). The Widely Used ATB FUNGUS 3 Automated Readings in China and Its Misleading High MICs of Candida spp. To Azoles: Challenges for Developing Countries' Clinical Microbiology Labs. PLoS ONE 9(12):e114004. |
|
Copyright © 2024 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0
